HB

If You Purchased a Huda Beauty Neon Obsessions Pressed Pigment Palette, You May Be Eligible for a Cash Refund up to $87 With Proof of Purchase from a Class Action Settlement

Thursday, October 14, 2021 - 2:00pm

A Proposed Settlement has been reached in a class action lawsuit.Purchasers of Huda Beauty Neon Obsessions makeup palettes sued the distributors, HB USA Holdings, Inc. dba Huda Beauty, alleging violations of laws relating to the sale of the Huda Beauty Neon Obsessions Pressed Pigment Products (the "Products").

Key Points: 
  • A Proposed Settlement has been reached in a class action lawsuit.Purchasers of Huda Beauty Neon Obsessions makeup palettes sued the distributors, HB USA Holdings, Inc. dba Huda Beauty, alleging violations of laws relating to the sale of the Huda Beauty Neon Obsessions Pressed Pigment Products (the "Products").
  • If you don't submit a timely Claim Form and don't exclude yourself from the settlement, you will be bound by the settlement and will not receive a Cash Payment.
  • You Can Object to the Settlement.You can ask the Court to deny approval by objecting with the Court.
  • Class members who are unable to provide valid Proof of Purchase shall be eligible to submit a claim for payment of a total of Ten U.S.

Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Wednesday, October 13, 2021 - 12:30pm

Additionally, during the open-label extension phase of this clinical trial, AD109 was shown to have a durability-of-effect when patients took AD109 for 28 days.

Key Points: 
  • Additionally, during the open-label extension phase of this clinical trial, AD109 was shown to have a durability-of-effect when patients took AD109 for 28 days.
  • Patients also experienced improvements in quality-of-life, nighttime breathing, and sleep across both objective and subjective measures.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with Obstructive Sleep Apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease

Wednesday, October 13, 2021 - 12:30pm

Both doses studied in this clinical trial led to statistically significant improvements across multiple measures of disease severity and demonstrated clear evidence of a dose-response.

Key Points: 
  • Both doses studied in this clinical trial led to statistically significant improvements across multiple measures of disease severity and demonstrated clear evidence of a dose-response.
  • We plan to initiate a third Phase 2 confirmatory study, called MARIPOSA, which is slated to start later this year.
  • Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea patients with Obstructive Sleep Apnea will benefit from treatment with a safe and effective oral medication.
  • Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Global Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness - ResearchAndMarkets.com

Tuesday, October 5, 2021 - 11:22am

Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

Key Points: 
  • Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.
  • Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate.
  • The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy.
  • Half of the global sickle cell anemia burden is present in India, Nigeria, and the Democratic Republic of the Congo

World-Renowned Celebrity Chefs Brought the Heat at Blue Diamond Resorts’ Gastronomic Food Festival

Wednesday, September 29, 2021 - 6:02pm

Seventeen celebrity chefs and eleven world-class mixologists and sommeliers provided endless entertainment during the seven-day event, giving guests the exclusive opportunity to experience world-renowned culinary excellence.

Key Points: 
  • Seventeen celebrity chefs and eleven world-class mixologists and sommeliers provided endless entertainment during the seven-day event, giving guests the exclusive opportunity to experience world-renowned culinary excellence.
  • Connecting Blue Diamond Resorts passion for food and drink with the best culinary talent in the world translated to an indescribable guest experience and memories that will last a lifetime, says Erik Peters, Corporate Food and Beverage Director of Blue Diamond Resorts.
  • Blue Diamond Resorts was thrilled to welcome HB S-Delli as the title sponsor of the Food + Drink Experience, alongside key sponsors Encore, Pilsa, and Front of House.
  • Since its inception in 2011, Blue Diamond Resorts has curated an impressive portfolio encompassing 45 properties, exceeding 15,000 rooms in ten countries.

Corporate Accountability Action Launches #OfftheBANWagon Campaign To Hold Financial Backers of Texas Abortion Ban Accountable

Thursday, September 23, 2021 - 2:15pm

The new project will shine a light on the corporations that have bankrolled the campaigns of the Texas state legislators who sponsored this cruel abortion ban.

Key Points: 
  • The new project will shine a light on the corporations that have bankrolled the campaigns of the Texas state legislators who sponsored this cruel abortion ban.
  • As a result of the Texas ban, state legislatures across the country are considering extreme abortion ban laws of their own, taking away long-established reproductive rights.
  • The #OffTheBANWagon campaign, a project of Corporate Accountability Action and American Bridge 21st Century, will be releasing advertisements focused on educating Texas residents on the corporate backers of the ban, along with the critical role these major corporations played in the ultimate passing of the law.
  • To learn more about how to hold these corporations accountable, visit OffTheBANWagon.org or Twitter @CAAction2021 , Facebook at / corporateaccountabilityaction , or on Instagram @corporateaccountabilityaction .

Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis

Thursday, September 9, 2021 - 12:30pm

CAMBRIDGE, Mass. and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), together with subsidiary ApcinteX Limited (“ApcinteX”), today announced positive topline results from the Phase 2a part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients.

Key Points: 
  • All subjects had target joints at the start of the study and 15 subjects had zero target joints at the end of the study.
  • Centessa expects to report results from the OLE portion of this study in the second half of 2022.
  • We see broad utility of SerpinPC across the hemophilia landscape and will seek the most rapid path to bring this potential subcutaneous therapy to hemophilia patients, said Antoine Yver, M.D., M.Sc., Chief Medical Officer of Centessa Pharmaceuticals.
  • Centessa Pharmaceuticals will host a webcast and conference call today, September 9, 2021, at 8:30 a.m. EDT to discuss topline data from the proof-of-concept trial.

Tonto Apache and Quechan Tribes Prepare to Launch Sports Betting in Arizona While Fighting Legal Effort to Stop It

Saturday, September 4, 2021 - 1:03am

The Tonto Apache and Quechan Tribes are represented by Rosette, LLP.

Key Points: 
  • The Tonto Apache and Quechan Tribes are represented by Rosette, LLP.
  • Doug Ducey and 20 of Arizona's 22 federally recognized Indian tribes, including the rural Tonto Apache and Quechan tribes.
  • Both were among the ten tribes that applied for and were awarded sports betting licenses under the new law.
  • The Tonto and Quechan tribes have filed a notice of intent to intervene in the legal action, and will also pursue a motion to dismiss as needed.

HQ Capital Real Estate Finalizes Strategic Partnership, Announces Rebrand as ‘CP Capital’

Monday, August 30, 2021 - 2:00pm

HQ Capital Real Estate, a highly disciplined U.S. real estate manager specializing in multifamily investments, today announced it has closed on its transaction with Concord Pacific and Paragon Real Estate Advisors (a subsidiary of HB Management) and rebranded to CP Capital.

Key Points: 
  • HQ Capital Real Estate, a highly disciplined U.S. real estate manager specializing in multifamily investments, today announced it has closed on its transaction with Concord Pacific and Paragon Real Estate Advisors (a subsidiary of HB Management) and rebranded to CP Capital.
  • By integrating our expertise with their already successful investment acumen, we believe CP Capital is perfectly positioned to capture opportunities in the U.S. real estate market, said Dr. Bernd Trk, CEO of HQ Capital.
  • Since its inception as Real Estate Capital Partners in 1989, CP Capital has invested in approximately $15 billion of U.S. real estate through sponsored funds and separate accounts on behalf of global institutions, family offices and ultra-high net worth individuals.
  • CP Capital, formerly known as HQ Capital Real Estate, is a highly disciplined U.S. real estate investment manager focused on the multifamily sector.

Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates

Monday, August 16, 2021 - 12:00pm

CAMBRIDGE, Mass. and LONDON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today reported financial results for the quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.

Key Points: 
  • and LONDON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today reported financial results for the quarter ended June 30, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones.
  • $379.5 Million Initial Public Offering (IPO) Successfully Completed: In the second quarter, Centessa closed its initial public offering of 16,500,000 American Depositary Shares (ADSs).
  • The gross proceeds to Centessa from its IPO, before deducting underwriting discounts, commissions and other estimated offering expenses, totaled an aggregate of $379.5 million.
  • The Phase 2a has completed dosing and the Company anticipates sharing topline results in the third quarter of 2021.